Financing & Funds
Penn cell and gene therapy spinout Interius Biotherapeutics raises another $21.5M. The 4-year-old company has now raised nearly $100 million since its inception, including the $76 million it raised last year in a Series A round co-led by Boston-based Cormorant Asset Management and
